SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001437749-19-022151
Filing Date
2019-11-08
Accepted
2019-11-08 16:06:35
Documents
69
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q navb20190930_10q.htm 10-Q 1146368
2 EXHIBIT 31.1 ex_163504.htm EX-31.1 9362
3 EXHIBIT 32.1 ex_163505.htm EX-32.1 4777
  Complete submission text file 0001437749-19-022151.txt   6732177

Data Files

Seq Description Document Type Size
4 XBRL INSTANCE DOCUMENT navb-20190930.xml EX-101.INS 1533643
5 XBRL TAXONOMY EXTENSION SCHEMA navb-20190930.xsd EX-101.SCH 55661
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE navb-20190930_cal.xml EX-101.CAL 41101
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20190930_def.xml EX-101.DEF 494072
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20190930_lab.xml EX-101.LAB 374182
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20190930_pre.xml EX-101.PRE 511758
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35076 | Film No.: 191204094
SIC: 2835 In Vitro & In Vivo Diagnostic Substances